Pharmaceuticals

Pfizer (NYSE: PFE) CEO Ian Read has his hands full, as Pfizer looks for ways to increase its stock's value with patents set to expire on many of its key drugs. Buybacks and asset divestitures are a couple of options for ways to enhance the value of Pfizer stock. Pfizer has begun buying back stock...

Shares of Salix Pharmaceuticals (NASDAQ: SLXP) are higher on the session by 0.11%, trading at $43.96. Overall put volume is now running at 22.17x the daily average, with 4% of all puts traded being purchases on the offer. 1,530 contracts have traded on the session so far. Salix Pharmaceuticals,...

Piper Jaffray released its Medical Technology & Hospital Supplies update today after attending the Current Concepts in Joint Replacement meeting (CCJR). In a note to clients, Piper Jaffray writes, "We came away from the CCJR meeting with a mixed bag of feedback regarding the outlook for volume...

VIVUS, Inc. (NASDAQ: VVUS) is up in pre-market trading, and its competitors, Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Orexigen Therapeutics, Inc. (NASDAQ: OREX) could see some buying interest in sympathy. Shares of VVUS are up 15 cents to $9.54 in pre-market trading. VIVUS engages in the...

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) earlier today announced that Robert A. Ingram, Valeant's lead independent director, was appointed as Chairman of the Board of Directors, replacing William M. Wells, who has resigned from the Board to pursue other interests.

Cypress Bioscience, Inc. (CYPB) shares gained more than 21% following the announcement of a revised offer from Ramius LLC. On December 9, 2010, Ramius approached Cypress Bio with a revised offer of $5.50 per share for the outstanding common shares of the company that it does not already own....

Cypress Bioscience, Inc. (CYPB) shares gained more than 21% following the announcement of a revised offer from Ramius LLC. On December 9, 2010, Ramius approached Cypress Bio with a revised offer of $5.50 per share for the outstanding common shares of the company that it does not already own....

Sanofi-Aventis' (SNY) third quarter EPADS of $1.22 was above the Zacks Consensus Estimate of $1.17 but a couple of cents below the year-ago earnings. We are encouraged to see Sanofi's progress with its pipeline. While new product launches should make significant revenue contributions in the early...

Sanofi-Aventis' (SNY) third quarter EPADS of $1.22 was above the Zacks Consensus Estimate of $1.17 but a couple of cents below the year-ago earnings. We are encouraged to see Sanofi's progress with its pipeline. While new product launches should make significant revenue contributions in the early...

We are maintaining our Neutral recommendation on MannKind Corporation (MNKD) with a target price of $7.50. MannKind is a Valencia, California-based biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diabetes, cancer and inflammatory...

We are maintaining our Neutral recommendation on MannKind Corporation (MNKD) with a target price of $7.50. MannKind is a Valencia, California-based biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diabetes, cancer and inflammatory...

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that the company has filed a Citizen Petition with the U.S. Food and Drug Administration requesting that the FDA refuse to approve any abbreviated new drug application for a purported generic version of COPAXONE.

Recently, Novartis AG (NVS) presented data from a phase II study of its blood cancer pipeline drug LBH589 at the annual meeting of the American Society of Hematology (ASH). The phase II pivotal study showed sustained anticancer activity in extensively pretreated Hodgkin lymphoma patients who...